Context Identifying the most effective first-line treatment for metastatic renal cell carcinoma
(mRCC) is challenging as rapidly evolving data quickly outdate the existing body of …

Purpose Management of metastatic renal cell cancer (mRCC) has undergone a paradigm
shift with immune-checkpoint inhibitors (ICI) in the first-line setting. However, direct …

The aim of this study was to assess the utility of neutrophil-to-lymphocyte ratio (NLR), plate-
let-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) as predictive …

Background Treatment of metastatic renal cell carcinoma (mRCC) is rapidly evolving with
new combination therapies demonstrating improved response rates and survival. There are …

Renal cell carcinoma (RCC) is the sixth most common cancer in the US. However, no
significant changes in management have occurred since the tyrosine kinase era until the …

Introduction Combined axitinib and immuno-oncology (IO) therapy is approved for first-line
advanced renal cell carcinoma. Overlapping toxicities represent a clinical challenge …

While immune checkpoint inhibitors (ICI) can lead to sustained responses in metastatic renal
cell carcinoma (mRCC), the optimal duration of therapy remains unknown. We aimed to …

Objectives To investigate the prognostic impact of tumor burden in patients receiving
nivolumab plus ipilimumab as first-line therapy for previously untreated metastatic renal cell …

Background This study compared real-world outcomes of metastatic renal-cell carcinoma
(mRCC) patients treated with tyrosine kinase inhibitors or nivolumab plus ipilimumab …

Over the last decade, there have been substantial progress in the field of systemic therapy
for advanced renal cell carcinoma. Through the transition from treatment with cytokines to …